VADUZ, Liechtenstein, May 9, 2025 /PRNewswire/ -- Global expansion of RefluxStop™ Significant events in the first quarter of 2025 Received positive feedback from U.S. FDA on our Clinical Module 2 Premarket Approval (PMA) application. FDA accepted Module 1 containing the quality systems and manufacturing information for RefluxStop™, and this module is now considered closed. Results from the largest real-world RefluxStop™ study published, involving 79 patients for up to 17 months follow-up in Germ

Company Transitioned onto the OTC Pink CRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together

Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.​ The trial was not statistically powered to formally test overall surviv

Uppsala, Sweden – May 9, 2025 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that Friedrich von Bohlen, CEO of Molecular Health AG and active in three boards, including Orexo’s since the end of 2024, has been appointed chairman of the board. The resolution was adopted at the annual general meeting held on May 8, 2025. Friedrich von Bohlen replaces James Noble, who has held the position since 2020 and has declined re-election. Friedrich von Bohlen, based in Germany, has over 25 years of ex

$1M grant awarded for wearable X-ray project University of Queensland researchers are creating an X-ray detector that can be worn in hoodies or blankets to get a quick, accurate scan of children's lungs. Their project is adapting patented quantum dot hybrid glass into thin film strips that conform to the contour and movement of a child's body. It has received A$1.6 million ($1 million) grant funding over five years from the National Health and Medical Research Council to address difficulties i

TORONTO, May 8, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is aware of the dissident proxy circular filed on May 7, 2025 (the "Dissident Circular") by Apollo Technology Capital Corporation ("Apollo"). The Dissident Circular outlines Apollo's intention to nominate six individuals for election to MediPharm's board of directors ("Board") at the Company's upcoming Annual and Special Meetin

LEQVIO marks a significant advancement in hypercholesterolemia management, particularly for patients not achieving target LDL-C levels despite maximally tolerated statin therapy. As the first FDA-approved siRNA therapy for LDL-C reduction, it introduces a novel mechanism of action with sustained efficacy and biannual dosing, enhancing patient adherence. LAS VEGAS, May 8, 2025 /PRNewswire/ -- DelveInsight's " LEQVIO Market Size, Forecast, and Market Insight Report" highlights the details around L

As a novel calcineurin inhibitor with proven efficacy in improving renal outcomes, LUPKYNIS addresses a high unmet medical need. With increasing awareness, supportive guidelines, and potential global expansion, it is well-positioned for steady market growth. LAS VEGAS, May 8, 2025 /PRNewswire/ -- DelveInsight's " LUPKYNIS Market Size, Forecast, and Market Insight Report" highlights the details around LUPKYNIS, the first oral lupus nephritis-specific treatment, which has expanded the therapeutic

Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution. Responder analyses demonstrate statistically significant symptom resolution across multiple endpoints in PL9643-treated patients compared to placebo. 6 of 13 symptom endpoints reached statistical significance (p<0.05). This level of symptom clearing has not been demonstrated by any currently approved dry eye disease therapy. Symptom resolution was observed as early as two weeks

BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally. About BioLife Solutions BioLife is a leading deve